• Accelerates how oncology teams assess study feasibility, size opportunity, and generate real-world intelligence
• Flexible interface and advanced capabilities enable life sciences teams address complex questions, uncover opportunity, and make faster, evidence-driven decisions

NEW YORK--(BUSINESS WIRE)--May 19, 2026-- Flatiron Health today announced the launch of Flatiron Telescope, a next-generation AI-powered platform designed to help life sciences teams and researchers find the right patients faster, assess study feasibility in real time, and generate oncology insights on demand.

Built on Flatiron’s industry-leading real-world data and powered by its multi-agent adaptive analytics engine, Flatiron Telescope enables teams across clinical development, RWE, and commercial functions to move from hypothesis to insight in minutes—not months.

“As oncology becomes more complex, the ability to quickly identify the right patients and answer critical research questions is no longer a nice-to-have, it’s essential,” said Kate Estep, Chief Product Officer at Flatiron Health. “With Flatiron Telescope, we’re bringing together trusted data, AI-powered intelligence, and deep oncology expertise into a single platform that helps teams answer questions faster and make better decisions.”

Flatiron Telescope delivers a faster path from question to insight—fundamentally transforming how teams interact with real-world data. With the ability to translate complex inclusion and exclusion criteria into actionable patient cohorts using natural language, non-technical users can move from data to decisions in minutes, without writing a single line of code. As criteria are refined, patient counts and attrition update in real time, giving teams immediate visibility into feasibility constraints. Users can dynamically stratify cohorts by biomarkers, lines of therapy, and treatment history, and generate patient characteristics, treatment patterns, and survival analyses on demand—eliminating the need to wait in analyst queues and accelerating the path to decision-making.

Purpose-built for oncology, Flatiron Telescope is powered by the depth and rigor of Flatiron’s real-world data. The platform leverages more than 15 years of longitudinal data from over 4,700 providers and 1,600 sites—representing roughly two in five patients with cancer—alongside a growing global network spanning the US, UK, Germany, and Japan, and capturing insights from more than 5 million patient journeys. With source-document traceability, multimodal data linkages, and validated real-world clinical data grounded in Flatiron’s peer-reviewed VALID Framework, Telescope brings a level of scientific and clinical rigor that teams can trust.

At its core, Flatiron Telescope is powered by Flatiron’s multi-agent adaptive analytics engine, enabling users to ask complex oncology questions in natural language and generate insights instantly. The platform is fine-tuned on more than 15 years of oncology research workflows and evidence generation, combining AI-powered analytics with the scientific and clinical expertise behind thousands of real-world studies.

By bringing together data, analytics, and intuitive design in a single platform, Flatiron Telescope democratizes access to oncology insights across organizations. Clinical, RWE, and commercial teams alike can explore data, build cohorts, and generate insights—without specialized technical expertise. Whether assessing study feasibility, sizing a market, or evaluating outcomes, Flatiron Telescope enables teams to reduce risk in indication and population selection, accelerate study planning and execution, and make data-driven decisions on the largest research-grade real-world oncology database.

About Flatiron
Flatiron Health transforms cancer care and research through a unified, global oncology engine powered by expert-validated AI and deep clinical and scientific expertise. Built from the experiences of millions of patients across the US, UK, Germany, and Japan, our real-world evidence informs the research, regulatory, commercial, and treatment decisions shaping oncology today. In the US, our point-of-care technology empowers clinicians to deliver smarter, more connected care while generating deeper insights that help advance cancer research. Flatiron Health is an independent affiliate of the Roche Group. Flatiron.com @FlatironHealth

View source version on businesswire.com: https://www.businesswire.com/news/home/20260519371207/en/

Media Contact
Nina Toor
press@flatiron.com

Source: Flatiron Health